IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Stefan Golz, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2004/010383

Title: Diagnostics and Therapeutics for Diseases Associated with G-Protein

Coupled Receptor ADIPOR2 (ADIPOR2)

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY 37 C.F.R. 1.97(b)(2)

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO].

A copy of the International Search Report prepared by the European Patent Office is also enclosed under 37 CFR 1.492(b)(3).

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Susan M. Pellegrino Reg. No.: 48,972

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 Telephone: (203) 812-6450

Facsimile: (203) 812-6459

VAPORES STATIFFED 20 MAR 2008

PTO/SB/08A (07-05) Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Substitute for form 1449/	PTO		Complete if Known		
				Application Number	[to be assigned]	
	INFORMAT	ION DISC	OSLIDE	Filing Date		
				First Named Inventor	Stefan Golz	· · · · · · · · · · · · · · · · · · ·
	STATEMEN			Art Unit		
	(Use as ma	ny sheets as nece	essary)	Examiner Name		
Sh	eet 1	of	2	Attorney Docket Number	Le A 36 902	

			U. S. PATENT D		
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		US-			
		US-	 		
		US-		AND A COLUMN TO THE STATE OF TH	
		US-			
		US-			
		US-			
		US-		***************************************	•
		US-			-7-4-1
-		US-			
		US-			
		US-			
	- ''-	US-			
		US-			

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)		The state of the s		Т
	F1	WO 2004/061108 A1	22-07-2004	Center for Advanced So	ience and	
				Technology Incubation,	Ltd.	Γ
	F2	WO 2004/063711 A2	29-07-2004	Beth Israel Deaconess	Medical Center	
	F3	WO 02/072149 A1	19-09-2002	Oklahoma Medical Res	earch Foundation	Γ

Examiner	Date	
Signature		
Signature	I Consid	ered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IAPS FIST'S PCT/PTO 2 0 MAR 2006

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMEDIE

Substitute for form 1449/PTO				re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
				Application Number	[to be assigned]	
INFO	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date		
STAT				First Named Inventor	Stefan GOLZ	
(Use as many sheets as necessary)			20000001	Art Unit		
			cessary	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	Le A 36 902	

		NON PATENT LITERATURE DOCUMENTS	-
Examiner Initials*			
	R1	Yamauchi, T., et al., "Cloning of Adiponectin Receptors that Mediate Antidiabetic Metabolic Effects", Nature, 423: 762-769 (June 2003)	
	R2	Yamauchi, T., et al., "The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity", Nature Medicine, 7(8): 941-946 (August 2001)	

Examiner	Date
Signature	Considered
*EVALUED Life-19 4	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.